Last €74.67 EUR
Change Today +2.44 / 3.39%
Volume 225.0
PY2 On Other Exchanges
As of 10:16 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

pharmacyclics inc (PY2) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - €111.83
52 Week Low
04/14/14 - €61.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMACYCLICS INC (PY2)

pharmacyclics inc (PY2) Related Businessweek News

View More BusinessWeek News

pharmacyclics inc (PY2) Details

Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company’s clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.

499 Employees
Last Reported Date: 05/8/14
Founded in 1991

pharmacyclics inc (PY2) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $541.1K
Chief Operating Officer
Total Annual Compensation: $849.2K
Executive Vice President of Corporate Affairs
Total Annual Compensation: $126.2K
Chief of Quality & Technical Operations
Total Annual Compensation: $704.3K
Compensation as of Fiscal Year 2013.

pharmacyclics inc (PY2) Key Developments

Pharmacyclics Inc. Announces Encouraging Results from Lymphocytic Leukemia Study

Pharmacyclics Inc. has announced that IMBRUVICA in combination with the anti-CD20 antibody, ofatumumab, showed a Kaplan Meier estimate of continued clinical response at 18 months of 82.5% in heavily pre-treated patients with chronic lymphoma leukemia, or CLL, small lymphocytic leukemia, or SLL, prolymphocytic leukemia, or PLL, and Richters Transformation, or RT. The median duration of response for all dosing schedules in this study was not reached. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech Inc. The study design consisted of three dosing cohorts, group 1 received one month of IMBRUVICA monotherapy followed by IMBRUVICA and ofatumumab in combination thereafter, group 2 received IMBRUVICA and ofatumumab in combination from the outset, and group 3 received two months of ofatumumab monotherapy followed by IMBRUVICA and ofatumumab thereafter.

U.S. Food and Drug Administration Accepts Pharmacyclics, Inc.'s Supplemental New Drug Application to Support the Review of IMBRUVICA

Pharmacyclics Inc. announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval. The sNDA was submitted to the FDA based on data from the randomized, multi-center, open label Phase III RESONATE(TM) trial, PCYC-1112-CA, a head-to-head comparison of IMBRUVICA(TM) versus ofatumumab in 391 patients with CLL or SLL who had received at least one prior therapy. The target date as defined by the Prescription Drug User Fee Act by which the FDA is planning to finalize the review of this application (PDUFA date) is October 7, 2014.

Pharmacyclics Inc. Announces the Resignation of Paula Boultbee as Employee of the Company

Effective May 20, 2014, Paula Boultbee, a named executive officer of Pharmacyclics Inc., resigned as an employee of the Company. Paula recently worked together with collaboration partner Janssen on IMBRUVICA related non-US commercial strategies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PY2:GR €74.67 EUR +2.44

PY2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celgene Corp $88.94 USD +2.28
View Industry Companies

Industry Analysis


Industry Average

Valuation PY2 Industry Range
Price/Earnings 55.5x
Price/Sales 19.2x
Price/Book 10.9x
Price/Cash Flow 52.8x
TEV/Sales 17.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at